Search results
Results from the WOW.Com Content Network
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; [2] it is a type of viral hepatitis. [6] During the initial infection period, people often have mild or no symptoms. [1] Early symptoms can include fever, dark urine, abdominal pain, and yellow tinged skin. [1]
The hepatitis C virus (HCV) [3] is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer ( hepatocellular carcinoma , abbreviated HCC) and lymphomas in humans.
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. [8] It is a fixed-dose combination of ledipasvir and sofosbuvir. [8] Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. [9] Some evidence also supports use in HCV genotype 3 and 4. [9]
“Hepatitis C is a blood-borne virus,” says Dr. Dieterich. “It is transmitted through the blood, so IV drug use is a major driver of the virus, especially now due to the heroin epidemic.
Hepatitis A and E are mainly spread by contaminated food and water. [3] Hepatitis B is mainly sexually transmitted, but may also be passed from mother to baby during pregnancy or childbirth and spread through infected blood. [3] Hepatitis C is commonly spread through infected blood such as may occur during needle sharing by intravenous drug ...
Hepatitis C is a contagious disease that primarily affects the liver, causing severe damage as the disease progresses. [1] It is caused by the Hepatitis C virus , a small, enveloped RNA virus. The transmission of hepatitis C is through the contact with the blood of the infected person, for example by sharing the needles or by using non-sterile ...
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Grazoprevir is a drug [1] approved for the treatment of hepatitis C.It was developed by Merck and completed Phase III trials, used in combination with the NS5A replication complex inhibitor elbasvir under the trade name Zepatier, either with or without ribavirin.